GLP-1 Obesity Drugs Show Heart-Benefit Breakthrough

GLP-1 Obesity Drugs Show Heart-Benefit Breakthrough

New clinical trial data reveals significant cardiovascular protection, potentially redefining obesity treatment as preventive cardiology. Novo Nordisk’s latest trial of semaglutide (Wegovy) has up...